Carboxymethyl starch and lecithin complex as matrix for targeted drug delivery: I. Monolithic Mesalamine forms for colon delivery

被引:41
作者
Friciu, Maria Mihaela [1 ]
Tien Canh Le [1 ]
Ispas-Szabo, Pompilia [1 ]
Mateescu, Mircea Alexandru [1 ]
机构
[1] Univ Quebec, Dept Chem, Montreal, PQ H3C 3P8, Canada
关键词
Carboxymethyl starch; Lecithin; Complex; Colon delivery; High drug loading; Mesalamine; HIGH-AMYLOSE STARCH; PHYSICOCHEMICAL PROPERTIES; INCLUSION COMPLEXES; ULCERATIVE-COLITIS; POTATO STARCH; IN-VITRO; RELEASE; FORMULATIONS; CHITOSAN; TABLETS;
D O I
10.1016/j.ejpb.2013.03.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For drugs expected to act locally in the colon, and for successful treatment, a delivery device is necessary, in order to limit the systemic absorption which decreases effectiveness and causes important side effects. Various delayed release systems are currently commercialized; most of them based on pH-dependent release which is sensitive to gastrointestinal pH variation. This study proposes a novel excipient for colon delivery. This new preparation consists in the complexation between carboxymethyl starch (CMS) and Lecithin (L). As opposed to existing excipients, the new complex is pH-independent, inexpensive, and easy to manufacture and allows a high drug loading. FTIR, X-ray, and SEM structural analysis all support the hypothesis of the formation of a complex. By minor variation of the excipient content within the tablet, it is possible to modulate the release time and delivery at specific sites of the gastrointestinal tract. This study opens the door to a new pH-independent delivery system for mesalamine targeted administration. Our novel formulation fits well with the posology of mesalamine, used in the treatment of Inflammatory Bowel Disease (IBD), which requires repeated administrations (1 g orally four times a day) to maintain a good quality of life. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:521 / 530
页数:10
相关论文
共 38 条
  • [1] [Anonymous], 2010, US PHARM NAT FORM
  • [2] Polyelectrolyte complex of carboxymethyl starch and chitosan as drug carrier for oral administration
    Assaad, Elias
    Wang, Yu Juan
    Zhu, Xiao Xia
    Mateescu, Mircea Alexandru
    [J]. CARBOHYDRATE POLYMERS, 2011, 84 (04) : 1399 - 1407
  • [3] The influence of protonation ratio on properties of carboxymethyl starch excipient at various substitution degrees: Structural insights and drug release kinetics
    Assaad, Elias
    Mateescu, Mircea Alexandru
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 394 (1-2) : 75 - 84
  • [4] Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies
    Baumgart, Daniel C.
    Sandborn, William J.
    [J]. LANCET, 2007, 369 (9573) : 1641 - 1657
  • [5] Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations
    Calinescu, C
    Mulhbacher, J
    Nadeau, T
    Fairbrother, JM
    Mateescu, MA
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 60 (01) : 53 - 60
  • [6] Carboxymethyl high amylose starch: Chitosan self-stabilized matrix for probiotic colon delivery
    Calinescu, Carmen
    Mateescu, Mircea Alexandru
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2008, 70 (02) : 582 - 589
  • [7] Carboxymethyl high amylose starch for F4 fimbriae gastro-resistant oral formulation
    Calinescu, Carmen
    Nadeau, Eric
    Mulhbacher, Jerome
    Fairbrother, John Morris
    Mateescu, Mircea-Alexandru
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 343 (1-2) : 18 - 25
  • [8] Guidelines for the management of inflammatory bowel disease in adults
    Carter, MJ
    Lobo, AJ
    Travis, SPL
    [J]. GUT, 2004, 53 : v1 - v16
  • [9] New dissolution method for mesalamine tablets and capsules
    Chuong, Monica C.
    Christensen, J. Mark
    Ayresz, James W.
    [J]. DISSOLUTION TECHNOLOGIES, 2008, 15 (03): : 7 - 14
  • [10] Colombo, 2000, Pharm Sci Technol Today, V3, P198, DOI 10.1016/S1461-5347(00)00269-8